Antimicrobial Resistance (AMR) is a world-wide crisis caused by ongoing evolution of bacteria
APT’s phage bank uniquely adapts in spectrum of coverage to overcome emerging bacterial resistance. Our approach addresses today’s – and tomorrow’s – toughest infections.
The Diminishing Effectiveness
The useful lifespan of new antibiotics has suffered due to the emergence of bacterial resistance. This cycle of introducing a new drug only to have bacteria evolve resistance is the pattern that APT’s ever-expanding phage bank is designed to break.
This graphic shows the introduction of new classes of antibiotics, and the emergence of resistance to those drugs:
Data: CDC Report on Drug Resistance
Precise superbug therapy
Adaptive Phage Therapeutics (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria.
APT’s approach arms us with the unique capability of adapting to the emergence of future antibiotic-resistant superbugs. Our phage bank’s precision targeted, genomically screened, and highly purified phage collection is dynamically expanding in response to the emergence of new strains of bacterial superbugs.
APT recognized as a leader in biotech
“Breakthrough Company of the Year”
2021 Biobuzz Awards
“Company To Watch”
2020, Life Science Leader
“Top 1% of Startups in the World”
2020, Startup Grind Global Conference
“The Emerging Life Science Company of the Year”
2020, Maryland Technology Council
“One of five biotech companies to watch in 2020”
“Emerging Business of the Year Finalist”
2019, Montgomery County Chamber
“A High-momentum Game-Changing Startup of 2019”
2019, CB Insights
In 2016 APT’s approach achieved its first in-human success with the rescue of a critically ill MDR infected patient: Tom Patterson, multi-drug resistant Acinetobacter baumannii survivor.
APT in the news
- Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot OsteomyelitisGAITHERSBURG, MD, May 17, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the first patient has been dosed in its DFO Adaptive Novel Care Evaluation (DANCE™) trial, a […]
- Infectious disease and the need for more optionsBy learning from the past, we may have a much better arsenal against antimicrobial-resistant bacteria in the near future.
- APT featured in Dutch BroadcastAdaptive Phage Therapeutics was featured in an April 28 broadcast in the Netherlands, Dokters van morgen, discussing the treatment of stubborn infections. The discussion regarding APT begins at the 35 minute mark and […]